



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/869,869	•		Stuart J. Knechtle	14028.0293U1	1262
23859				EXAMINER	
NEEDLE &	ROSEN	BERG, P.C.	GAMBEL, PHILLIP		
SUITE 1000 999 PEACH	TREE STE	REFT	ART UNIT	PAPER NUMBER	
ATLANTA,			1644		

DATE MAILED: 03/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

	Application No.	Applicant(s)	
	09/869,869	KNECHTLE ET AL.	
ĺ	Examiner	Art Unit	
	Phillip Gambel	1644	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 19 January 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires \_\_\_\_\_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **NOTICE OF APPEAL** 2. The Notice of Appeal was filed on \_\_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below): (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: \_\_\_\_\_. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a)  $\square$  will not be entered, or b)  $\boxtimes$  will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: PHILLIP GAMBEL, PH.D.J.D. Claim(s) allowed: PRIMARY EXAMINER
TO (600) Claim(s) objected to: Claim(s) rejected: 1-13 and 21-28. Claim(s) withdrawn from consideration: 14-20 and 29-33. **AFFIDAVIT OR OTHER EVIDENCE** 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. 

The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13/2 Other: \_\_\_ SEE ATTACKED 892 SEED LISTING APPLICANTE EXHIBIT

Continuation of 11. does NOT place the application in condition for allowance because: of the reasons of record.

Applicant's arguments and the examiner's rebuttal are esentially the same of record.

With respect to applicant's reliance upon VanBuskirk et al., JAMA 278: 1993-1999, 1997; the following is noted.

In addition to the statements relied upon by applicant, the section on Chronic Rejection on pages 1997-1998 of VanVuskirk et al. also stand for "One strong stimulus to their development (e.g. tissue-remodelling responses) is the onset of postransplant allosensitization, evident as an acute rejection episode, the produciton of donor-reactive alloantibodies or both. Also, "When analyzed in more detail, becomes apparent that the patient subpopulation with chronic rejection is generally the same patient subpopulations with previous acute rejection episodes. This illustrates the immunologic relationsihip between actue rejections which is primarily a pathologic inflammatory response and chronic rejection, which is primarily a pathologic tissue-remodeling responses. It also suggests that the incidence of chronic rejection may fall substantially in patients treated with new immunosuppressive agents that reduce the indicence of acute rejection episodes, posttransplant alloantibody production or both. Prophylactic strategies should be aimed at the risk factors for chronic rejection, with pharmacologic agents that interfere with physiologic and immunologic mediators of vascular trauma and strategies that completely avoid the development of acute rejection. Therefore, the prior art teachings are consistent with meeting and achieving the claimed therapeutic strategies.

Applciant's arguemnts have not been found persusiave. .